stoxline Quote Chart Rank Option Currency Glossary
  
Teva Pharmaceutical Industries Limited (TEVA)
14.43  0.29 (2.05%)    03-27 16:00
Open: 14.19
High: 14.45
Volume: 11,607,816
  
Pre. Close: 14.14
Low: 14.16
Market Cap: 16,176(M)
Technical analysis
2024-03-27 4:56:25 PM
Short term     
Mid term     
Targets 6-month :  16.87 1-year :  19.71
Resists First :  14.44 Second :  16.87
Pivot price 13.67
Supports First :  13.31 Second :  12.6
MAs MA(5) :  14.05 MA(20) :  13.61
MA(100) :  11.41 MA(250) :  9.8
MACD MACD :  0.3 Signal :  0.3
%K %D K(14,3) :  93 D(3) :  89.6
RSI RSI(14): 74.8
52-week High :  14.44 Low :  7.09
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TEVA ] has closed Bollinger Bands are 0.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 14.46 - 14.5 14.5 - 14.55
Low: 14.03 - 14.08 14.08 - 14.14
Close: 14.34 - 14.42 14.42 - 14.51
Company Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Headline News

Wed, 27 Mar 2024
Teva and Daiichi Sankyo named and shamed for UK code breaches - The Pharma Letter

Wed, 27 Mar 2024
Teva on track for seventh straight day of gains (NYSE:TEVA) - Seeking Alpha

Wed, 27 Mar 2024
Wellington Management Group LLP Increases Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) - Defense World

Tue, 26 Mar 2024
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet - Simply Wall St

Tue, 26 Mar 2024
Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership - Yahoo Finance

Mon, 25 Mar 2024
Teva Pharmaceutical Industries: Potential Outweighs Concerns (NYSE:TEVA) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 1,120 (M)
Shares Float 1,120 (M)
Held by Insiders 0 (%)
Held by Institutions 53.4 (%)
Shares Short 15,390 (K)
Shares Short P.Month 18,320 (K)
Stock Financials
EPS -0.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.69
Profit Margin -3.6 %
Operating Margin 28 %
Return on Assets (ttm) 4.5 %
Return on Equity (ttm) -7.4 %
Qtrly Rev. Growth 14.8 %
Gross Profit (p.s.) 0
Sales Per Share 14.15
EBITDA (p.s.) 3.86
Qtrly Earnings Growth 0 %
Operating Cash Flow 1,370 (M)
Levered Free Cash Flow 3,290 (M)
Stock Valuations
PE Ratio -28.87
PEG Ratio 3.5
Price to Book value 2.15
Price to Sales 1.01
Price to Cash Flow 11.79
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android